These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32351136)

  • 1. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
    Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
    J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.
    Patel VA; McCullum C; Sparks AD; Schmults CD; Arron ST; Jambusaria-Pahlajani A
    Cancer Med; 2022 Jan; 11(1):94-103. PubMed ID: 34796670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
    Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
    J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
    Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
    Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the American Joint Committee on Cancer Seventh Edition and Brigham and Women's Hospital Cutaneous Squamous Cell Carcinoma Tumor Staging in Immunosuppressed Patients.
    Gonzalez JL; Cunningham K; Silverman R; Madan E; Nguyen BM
    Dermatol Surg; 2017 Jun; 43(6):784-791. PubMed ID: 28079640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
    Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
    JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
    Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
    Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.
    Karia PS; Jambusaria-Pahlajani A; Harrington DP; Murphy GF; Qureshi AA; Schmults CD
    J Clin Oncol; 2014 Feb; 32(4):327-34. PubMed ID: 24366933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of Poor Outcomes for Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients Using the American Joint Committee on Cancer Eighth Edition and Brigham and Women's Hospital Staging Systems.
    Blechman AB; Carucci JA; Stevenson ML
    Dermatol Surg; 2019 Sep; 45(9):1117-1124. PubMed ID: 30640779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy.
    Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):760-771. PubMed ID: 38810706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.
    Cañueto J; Burguillo J; Moyano-Bueno D; Viñolas-Cuadros A; Conde-Ferreirós A; Corchete-Sánchez LA; Pérez-Losada J; Román-Curto C
    J Am Acad Dermatol; 2019 Jan; 80(1):106-113.e2. PubMed ID: 30003984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
    Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management.
    Arron ST; Blalock TW; Guenther JM; Hyams DM; Ibrahim SF; Koyfman SA; Wysong A
    J Drugs Dermatol; 2021 Jun; 20(6):5s-s11. PubMed ID: 34076385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
    Al-Rohil RN; Tarasen AJ; Carlson JA; Wang K; Johnson A; Yelensky R; Lipson D; Elvin JA; Vergilio JA; Ali SM; Suh J; Miller VA; Stephens PJ; Ganesan P; Janku F; Karp DD; Subbiah V; Mihm MC; Ross JS
    Cancer; 2016 Jan; 122(2):249-57. PubMed ID: 26479420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.